Document:

<PAGE>   1
                                                                   EXHIBIT 10.19

                AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT

         THIS AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT between GMP
Companies, Inc., as successor by merger of Global Medical Products, Inc. (the
"Company"), and the Investors named on the signatures pages hereto (this
"Agreement") is entered into as of March 29, 2000 and amends and restates in its
entirety the Investors' Rights Agreement dated September 15 1999 (the "Original
Agreement"), by and among Global Medical Products, Inc., Motorola, Inc.
("Motorola"), Seligman Communications and Information Fund, Inc., Seligman New
Technologies Fund, Inc., Seligman Investment Opportunities (Master) Fund - NTV
Portfolio (the "Seligman Funds") and certain other purchasers of Series A
Convertible Preferred Stock of the Company (together with Motorola and the
Seligman Funds, the "Investors").

RECITALS

         A.       The Company has issued and sold shares of its Series A
Preferred Stock to certain of the Investors and proposes to issue and sell up to
4,000,000 shares of its Series B Preferred Stock to certain of the Investors.

         B.       By this Agreement, the Company desires to provide for certain
registration and other rights to the Investors and certain additional rights to
TPG Partners III, L.P. ("TPG"), Motorola and Seligman as set forth herein.

AGREEMENT

         NOW, THEREFORE, in consideration of the foregoing and of the mutual
promises and covenants contained herein, the parties agree to amend and restate
in its entirety the Original Agreement as follows:

         1.       Registration Rights.

                  1.1      Certain Definitions. As used in this Agreement, the
following terms shall have the following respective meanings:

                           (a)      "Commission" shall mean the Securities and
Exchange Commission or any other federal agency at the time administering the
Securities Act.

                           (b)      "Conversion Stock" means the Company's
Common Stock, par value $.001 per share ("Common Stock"), issued or issuable
upon conversion of the Series A Preferred Stock or the Series B Preferred Stock.

                           (c)      "Exchange Act" shall mean the Securities
Exchange Act of 1934, as amended.

<PAGE>   2

                           (d)      "Holder" shall mean any party hereto holding
Registrable Securities and any person holding Registrable Securities to whom the
rights under this Section 1 have been transferred in accordance with Section
1.10.

                           (e)      "Initiating Holders" shall mean any Holder
or Holders of more than thirty percent (30%) of the then outstanding Registrable
Securities (adjusted after the original issuance thereof for stock splits, stock
dividends, recapitalizations and the like).

                           (f)      "Registrable Securities" means (i) the
Conversion Stock; and (ii) stock issued in respect of the stock referred to in
(i) as a result of a stock split, stock dividend, recapitalization or the like,
which has not been sold pursuant to an effective registration statement or Rule
144 under the Securities Act.

                           (g)      The terms "register," "registered" and
"registration" refer to a registration effected by preparing and filing a
registration statement in compliance with the Securities Act, and the
declaration or ordering of the effectiveness of such registration statement.

                           (h)      "Registration Expenses" shall mean all
expenses, except as otherwise stated below, incurred by the Company in complying
with Sections 1.2, 1.3 and 1.4 hereof, including, without limitation, all
registration, qualification and filing fees, printing expenses, escrow fees,
fees and disbursements of counsel for the Company, blue sky fees and expenses,
the expense of any special audits incident to or required by any such
registration (but excluding the compensation of regular employees of the Company
which shall be paid in any event by the Company) and the reasonable fees and
disbursements of one counsel for all Holders in the event of each registration
provided for in Sections 1.2, 1.3 and 1.4 hereof.

                           (i)      "Securities Act" shall mean the Securities
Act of 1933, as amended, or any similar federal statute and the rules and
regulations of the Commission thereunder, all as the same shall be in effect at
the time.

                           (j)      "Selling Expenses" shall mean all
underwriting discounts and selling commissions applicable to the securities
registered by the Holders.

                           (k)      "Series A Preferred Stock" shall mean the
Company's Series A Convertible Preferred Stock, par value $.01 per share.

                           (l)      "Series B Preferred Stock" shall mean the
Company's Series B Convertible Preferred Stock, par value $.01 per share.

                           (m)      "Stock" means and includes all shares of
Common Stock issued and outstanding at the relevant time plus (i) all shares of
Common Stock that may be issued upon exercise of any options, warrants and other
rights of any kind that are then exercisable, and (ii) all shares of Common
Stock that may be issued upon conversion of (A) any convertible securities,
including, without limitation, preferred stock and debt securities then
outstanding, which are by their terms then convertible into or exchangeable for
Common Stock or (B) any such convertible

                                       2
<PAGE>   3

securities that would then be exercisable and are issuable upon exercise of
options, warrants or other rights that are then exercisable.

                  1.2      Requested Registration.

                           (a)      Request for Registration. In case the
Company shall receive from Initiating Holders at any time beginning on the
earlier of (i) September 15, 2003, and (ii) six (6) months after the Company's
IPO (as defined below), a written request that the Company effect any
registration (1) of at least thirty percent (30%) of the Registrable Securities
then outstanding, or (2) for which the reasonably anticipated aggregate public
offering price would equal or exceed $7,500,000, the Company will:

                                    (i)      within fifteen (15) days of the
Company's receipt of such request, give written notice of the proposed
registration, qualification or compliance to all other Holders; and

                                    (ii)     as soon as practicable, or in any
event within ninety (90) days of the receipt of such request, use its best
efforts to effect such registration, qualification or compliance (including,
without limitation, appropriate qualification under applicable blue sky or other
state securities laws and appropriate compliance with applicable regulations
issued under the Securities Act and any other governmental requirements or
regulations) as may be so requested and as would permit or facilitate the sale
and distribution of all or such portion of such Registrable Securities as are
specified in such request, together with all or such portion of the Registrable
Securities of any Holder or Holders joining in such request as are specified in
a written request received by the Company within twenty (20) days after receipt
of such written notice from the Company; provided, however, that the Company
shall not be obligated to take any action to effect any such registration,
qualification or compliance pursuant to this Section 1.2:

                                             (A)      In any particular
jurisdiction in which the Company would be required to execute a general consent
to service of process in effecting such registration, qualification or
compliance unless the Company is already subject to service in such jurisdiction
and except as may be required by the Securities Act;

                                             (B)      At any time after five (5)
years following the effective date of the Company's initial public offering of
its securities for its own account pursuant to a registration statement declared
effective under the Securities Act ("IPO");

                                             (C)      After the Company has
undertaken two (2) such registrations pursuant to this Section 1.2(a) and such
registrations have been declared effective; provided, that if the Initiating
Holder is TPG, Motorola, or Seligman, such Initiating Holder shall have
participated in at least one of such registrations;

                                             (D)      If the Company shall
furnish to such Holders a certificate signed by the President of the Company
stating that in the good faith judgment of the

                                       3
<PAGE>   4

Board of Directors it would be seriously detrimental to the Company for a
registration statement to be filed in the near future, then the Company's
obligation to use its best efforts to register, qualify or comply under this
Section 1.2 shall be deferred for a period not to exceed ninety (90) days from
the date of receipt of written request from the Initiating Holders, provided
that the Company may not use this right more than once in any twelve (12) month
period;

                                             (E)      Within sixty (60) days
prior to or one hundred eighty (180) days following the effective date of the
IPO or a subsequent registered offering of the Company's equity securities; or

                                             (F)      If the Initiating Holders'
proposed sale of Registrable Securities may be immediately registered on Form
S-3 pursuant to Section 1.4 below.

                           (b)      Underwriting. In the event that a
registration pursuant to Section 1.2 is for a registered public offering
involving an underwriting, the Company shall so advise the Holders as part of
the notice given pursuant to Section 1.2(a)(i). In such event, the right of any
Holder to participate in such registration shall be conditioned upon such
Holder's participation in the underwriting arrangements required by this Section
1.2, and the inclusion of such Holder's Registrable Securities in the
underwriting to the extent requested shall be limited to the extent provided
herein.

         The Company shall (together with all Holders proposing to distribute
their securities through such underwriting) enter into an underwriting agreement
in customary form with the managing underwriter selected for such underwriting
by the Company and approved by a majority of the Holders proposing to distribute
their securities through such underwriting. Notwithstanding any other provision
of this Section 1.2, if the managing underwriter advises the Initiating Holders
in writing that marketing factors require a limitation of the number of shares
to be underwritten, then the Company shall so advise all participating Holders
and the number of shares of Registrable Securities that may be included in the
registration and underwriting shall be allocated among all Holders thereof in
proportion, as nearly as practicable, to the respective amounts of Registrable
Securities held by such Holders at the time of filing the registration
statement. No Registrable Securities excluded from the underwriting by reason of
the underwriter's marketing limitation shall be included in such registration.
To facilitate the allocation of shares in accordance with the above provisions,
the Company or the underwriters may round the number of shares allocated to any
Holder to the nearest 100 shares.

         If any Holder of Registrable Securities disapproves of the terms of the
underwriting, such person may elect to withdraw therefrom by written notice, on
or before the tenth (10th) day prior to the effectiveness of the registration
statement, to the Company, the managing underwriter and the Initiating Holders.
The Registrable Securities, and/or other securities so withdrawn shall also be
withdrawn from registration, and such securities shall not be transferred in a
public distribution prior to ninety (90) days after the effective date of such
registration, or other shorter period as the underwriters may require.

                                       4
<PAGE>   5

         If the underwriter has not limited the number of Registrable Securities
to be underwritten, the Company may include securities for its own account (or
for the account of other purchasers) in such registration to the extent the
managing underwriter so agrees and if the number of Registrable Securities that
would otherwise have been included in such registration and underwriting will
not thereby be limited.

                  1.3      Company Registration.

                           (a)      Notice of Registration. If at any time or
from time to time the Company shall determine to register any of its securities,
either for its own account or the account of a security holder or holders, other
than (i) a registration relating solely to employee benefit plans, (ii) a
registration relating solely to a transaction referred to in Rule 145 under the
Securities Act (a "Rule 145 transaction"), or (iii) a registration effected
pursuant to Sections 1.2 or 1.4 hereof, the Company will:

                                    (i)      notify each Holder of Registrable
Securities in writing at least thirty (30) days prior to filing any registration
statement under the Securities Act; and

                                    (ii)     include in such registration (and
any related qualification under blue sky laws or other compliance), and in any
underwriting involved therein, all the Registrable Securities specified in a
written request or requests, made within twenty (20) days after receipt of such
written notice from the Company, by any Holder.

                           (b)      Underwriting. If the registration of which
the Company gives notice is for a registered public offering involving an
underwriting, the Company shall so advise the Holders as a part of the written
notice given pursuant to Section 1.3(a)(i). In such event the right of any
Holder to registration pursuant to Section 1.3 shall be conditioned upon such
Holder's participation in such underwriting to the extent provided herein. All
Holders proposing to distribute their securities through such underwriting shall
(together with the Company and the other holders distributing their securities
through such underwriting) enter into an underwriting agreement in customary
form with the managing underwriter selected for such underwriting by the
Company. Notwithstanding any other provision of this Section 1.3, if the
managing underwriter determines that marketing factors require limitation of the
number of shares to be underwritten, the managing underwriter may limit the
Registrable Securities to be included in such registration. The Company shall so
advise all Holders and other holders distributing their securities through such
underwriting and the number of shares of securities that may be included in the
registration and underwriting (other than on behalf of the Company) shall be
allocated among all Holders and such other holders (provided that such other
holders have contractual rights to participate in such registration which are
not subordinate to the Holders) in proportion, as nearly as practicable, to the
respective amounts of Registrable Securities or other securities requested to be
included in such registration by such Holders and such other holders; provided,
however, in no event shall the amount of Registrable Securities of the Holders
included in the offering be reduced below twenty-five percent (25%) of the total
amount of securities included in such offering, unless such offering is the
Company's IPO in which case the Holders may be excluded entirely if the
underwriters make the determination described above or the Holders of a

                                       5
<PAGE>   6

majority of the Registrable Securities consent in writing to such a reduction.
To facilitate the allocation of shares in accordance with the above provisions,
the Company may round the number of shares allocated to any Holder or holder to
the nearest 100 shares. If any Holder disapproves of the terms of any such
underwriting, such Holder may elect to withdraw therefrom by written notice to
the Company and the managing underwriter. Except as set forth in Section 1.11,
any securities excluded or withdrawn from such underwriting shall be withdrawn
from such registration, and shall not be transferred in a public distribution
prior to ninety (90) days after the effective date of the registration statement
relating thereto, or such other shorter period of time as the underwriters may
require.

                  1.4      Registration on Form S-3.

                           (a)      In addition to any rights of the Holders
under Section 1.2, if a Holder or Holders of outstanding Registrable Securities
request that the Company file a registration statement on Form S-3 (or any
successor form to Form S-3) for a public offering of shares of Registrable
Securities the reasonably anticipated aggregate price to the public of which
would exceed $500,000, and the Company is a registrant entitled to use Form S-3
or such successor form to register the Registrable Securities for such an
offering, the Company shall use its best efforts to cause such Registrable
Securities to be registered for the offering on such form and to cause such
Registrable Securities to be qualified in such jurisdictions as the Holder or
Holders may reasonably request. The substantive provisions of Section 1.2(b)
shall be applicable to each registration initiated under this Section 1.4.

                           (b)      Notwithstanding the foregoing, the Company
shall not be obligated to take any action pursuant to this Section 1.4:

                                    (i)      in any particular jurisdiction in
which the Company would be required to execute a general consent to service of
process in effecting such registration, qualification or compliance unless the
Company is already subject to service in such jurisdiction and except as may be
required by the Securities Act;

                                    (ii)     if the Company, within ten (10)
days of the receipt of the request of the Holders, gives notice of its bona fide
intention to effect the filing of a registration statement with the Commission
within sixty (60) days of receipt of such request (other than with respect to a
registration statement relating to a Rule 145 transaction, an offering solely to
employees or any other registration which is not appropriate for the
registration of Registrable Securities);

                                    (iii)    within one hundred eighty (180)
days of the effective date of any registration referred to in Sections 1.2 and
1.3 above;

                                    (iv)     more than two (2) times in any
twelve (12) month period; or

                                       6
<PAGE>   7

                                    (v)      if the Company shall furnish to
such Holder a certificate signed by the President of the Company stating that in
the good faith judgment of the Board of Directors it would be seriously
detrimental to the Company for a registration statement to be filed in the near
future, then the Company's obligation to use its best efforts to file a
registration statement shall be deferred for a period not to exceed ninety (90)
days from the receipt of the request to file such registration by such Holder,
provided that the Company may not use this right more than once in any twelve
month period.

                  1.5      Expenses of Registration. Unless otherwise stated,
all Selling Expenses relating to securities registered on behalf of the Holders
shall be borne by the Holders of such securities pro rata on the basis of the
number of shares so registered. All Registration Expenses incurred in connection
with all registrations pursuant to Sections 1.2, 1.3 and 1.4 shall be borne by
the Company.

                  1.6      Registration Procedures. In the case of each
registration, qualification or compliance effected by the Company pursuant to
this Section 1, the Company will keep each Holder advised in writing as to the
initiation of each registration and as to the completion thereof. In carrying
out its obligations hereunder, at its expense the Company will, among other
things:

                           (a)      Prepare and file with the Commission an
appropriate registration statement with respect to such securities and the
intended method of distribution thereof and use its best efforts to cause such
registration statement to become and remain effective for at least one hundred
eighty (180) days or until the distribution described in the registration
statement has been completed;

                           (b)      Furnish to the Holders participating in such
registration and to the underwriters of the securities being registered such
reasonable number of copies of the registration statement, preliminary
prospectus, final prospectus and such other documents as such Holders and
underwriters may reasonably request in order to facilitate the public offering
of such securities.

                           (c)      Prepare and file with the Commission such
amendments and supplements to such registration statement and the prospectus
used in connection with such registration statement as may be necessary to
comply with the provisions of the Securities Act with respect to the disposition
of all securities covered by such registration statement in accordance with the
intended method of distribution thereof.

                           (d)      Use its best efforts to register and qualify
the securities covered by such registration statement under such other
securities or Blue Sky laws of such jurisdictions as shall be reasonably
requested by the Holders, provided that the Company shall not be required in
connection therewith or as a condition thereto to qualify to do business or to
file a general consent to service of process in any such states or
jurisdictions.

                           (e)      In the event of any underwritten public
offering, enter into and perform its obligations under an underwriting
agreement, in usual and customary form, with the

                                       7
<PAGE>   8

managing underwriter of such offering. Each Holder participating in such
underwriting shall also enter into and perform its obligations under such an
agreement.

                           (f)      Notify each Holder of Registrable Securities
covered by such registration statement at any time when a prospectus relating
thereto is required to be delivered under the Securities Act of the happening of
any event as a result of which the prospectus included in such registration
statement, as then in effect, includes an untrue statement of a material fact or
omits to state a material fact required to be stated therein or necessary to
make the statements therein not misleading in the light of the circumstances
then existing.

                           (g)      Use its best efforts to furnish, at the
request of any Holder requesting registration of Registrable Securities pursuant
to this Section 1, on the date that such Registrable Securities are delivered to
the underwriters for sale in connection with a registration pursuant to this
Section 1, if such securities are being sold through underwriters, or, if such
securities are not being sold through underwriters, on the date that the
registration statement with respect to such securities becomes effective, (i) an
opinion, dated such date, of the counsel representing the Company for the
purposes of such registration, in form and substance as is customarily given to
underwriters in an underwritten public offering, addressed to the underwriters,
if any, and to the Holders requesting registration of Registrable Securities and
(ii) a letter dated such date, from the independent certified public accountants
of the Company, in form and substance as is customarily given by independent
certified public accountants to underwriters in an underwritten public offering,
addressed to the underwriters, if any, and to the Holders requesting
registration of Registrable Securities.

                           (h)      Cause all such Registrable Securities
registered pursuant hereunder to be listed on each securities exchange on which
similar securities issued by the Company are then listed.

                           (i)      Provide a transfer agent and registrar for
all Registrable Securities registered pursuant hereunder and a CUSIP number for
all such Registrable Securities, in each case not later than the effective date
of such registration.

                  1.7      Indemnification.

                           (a)      The Company will indemnify each Holder, each
of its officers and directors, partners and affiliates, and each person
controlling such person within the meaning of Section 15 of the Securities Act,
in connection with any registration, qualification or compliance pursuant to
this Section 1, and each underwriter, if any, and each person who controls any
underwriter within the meaning of Section 15 of the Securities Act, against all
expenses, claims, losses, damages or liabilities (or actions in respect
thereof), including any of the foregoing incurred in settlement of any
litigation, commenced or threatened, arising out of or based on any untrue
statement (or alleged untrue statement) of a material fact contained in any
registration statement, prospectus, offering circular or other document, or any
amendment or supplement thereto, incident to any such registration,
qualification or compliance, or based on any omission (or alleged omission) to
state therein a material fact required to be stated therein or necessary to

                                       8
<PAGE>   9

make the statements therein, in light of the circumstances in which they were
made, not misleading, or any violation by the Company of the Securities Act or
any rule or regulation promulgated under the Securities Act applicable to the
Company in connection with any such registration, qualification or compliance,
and the Company will reimburse each such Holder, each of its officers,
directors, partners and affiliates and each person controlling any such person,
each such underwriter and each person who controls any such underwriter, for any
legal and any other expenses reasonably incurred in connection with
investigating, preparing or defending any such claim, loss, damage, liability or
action, provided that the Company will not be liable to any such person in any
such case to the extent that any such claim, loss, damage, liability or expense
arises out of or is based on any untrue statement or omission, made in reliance
upon and in conformity with written information furnished to the Company by an
instrument duly executed by or on behalf of such person and stated to be
specifically for use therein or the preparation thereof.

                           (b)      Each Holder will, if Registrable Securities
held by such Holder are included in the securities as to which such
registration, qualification or compliance is being effected, severally but not
jointly, indemnify the Company, each of its directors and officers, each
underwriter, if any, of the Company's securities covered by such a registration
statement, each person who controls the Company or such underwriter within the
meaning of Section 15 of the Securities Act, and each other such Holder, each of
its officers, partners, affiliates and directors and each person controlling any
such person within the meaning of Section 15 of the Securities Act, against all
claims, losses, damages and liabilities (or actions in respect thereof) arising
out of any untrue statement of a material fact contained in any registration
statement, prospectus, offering circular or other document, or any omission to
state therein a material fact required to be stated therein or necessary to make
the statements therein not misleading, and will reimburse the Company, such
Holders, such directors, officers, persons, underwriters or control persons for
any legal or any other expenses reasonably incurred in connection with
investigating, preparing or defending any such claim, loss, damage, liability or
action, in each case to the extent, but only to the extent, that such untrue
statement (or alleged untrue statement) or omission (or alleged omission) is
made in such registration statement, prospectus, offering circular or other
document in reliance upon and in conformity with written information furnished
to the Company by an instrument duly executed by such Holder and stated to be
specifically for use therein or the preparation thereof. Notwithstanding the
foregoing, the liability of each Holder under this subsection (b) shall be
limited to an amount equal to the net proceeds received by such Holder from the
sale of Registrable Securities held by such Holder in such registration.

                           (c)      Each party entitled to indemnification under
this Section 1.7 (the "Indemnified Party") shall give notice to the party
required to provide indemnification (the "Indemnifying Party") promptly after
such Indemnified Party has actual knowledge of any claim as to which indemnity
may be sought, and shall permit the Indemnifying Party to assume the defense of
any such claim or any litigation resulting therefrom, provided that counsel for
the Indemnifying Party, who shall conduct the defense of such claim or
litigation, shall be approved by the Indemnified Party (whose approval shall not
unreasonably be withheld), and the Indemnified Party may participate in such
defense at such party's expense, and provided further that the failure of any
Indemnified Party to give notice as provided herein shall not relieve the

                                       9
<PAGE>   10

Indemnifying Party of its obligations under this Section 1 except to the extent
that the failure to give such notice is materially prejudicial to an
Indemnifying Party's ability to defend such action and provided further, that
the Indemnified Party shall have the right to retain one separate counsel with
the reasonable fees and expenses to be paid by the Indemnifying Party, if
representation of such Indemnified Party by the counsel retained by the
Indemnifying Party would be inappropriate due to actual or potential differing
interests between such Indemnified Party and any other party represented by such
counsel in such proceeding. No Indemnifying Party, in the defense of any such
claim or litigation, shall, except with the consent of each Indemnified Party,
consent to entry of any judgment or enter into any settlement which does not
include as an unconditional term thereof the giving by the claimant or plaintiff
to such Indemnified Party a release from all liability in respect to such claim
or litigation.

                  1.8      Information by Holder. The Holders of securities
included in any registration shall furnish to the Company such information
regarding such Holders, the Registrable Securities held by them and the
distribution proposed by such Holders as the Company may request in writing and
as shall be required in connection with any registration, qualification or
compliance referred to in this Section 1.

                  1.9      Rule 144 Reporting. With a view to making available
the benefits of certain rules and regulations of the Commission which may at any
time permit the sale of the Registrable Securities to the public without
registration, after the Company's IPO, the Company agrees to use its best
efforts to:

                           (a)      Make and keep "current public information"
available, as that term is understood and defined in Rule 144 under the
Securities Act, at all times after the effective date that the Company becomes
subject to the reporting requirements of the Securities Act or the Exchange Act;

                           (b)      take such action, including the voluntary
registration of its Common Stock under Section 12 of the Exchange Act, as is
necessary to enable the Holders to utilize Form S-3 for the sale of their
Registrable Securities, such action to be taken as soon as practicable after the
end of the fiscal year in which the registration statement relating to the
Company's IPO is declared effective;

                           (c)      Use its best efforts to file with the
Commission in a timely manner all reports and other documents required of the
Company under the Securities Act and the Exchange Act (at any time after it has
become subject to such reporting requirements); and

                           (d)      So long as any party hereto owns any
Registrable Securities to furnish to such party forthwith upon request a written
statement by the Company as to its compliance with the reporting requirements of
said Rule 144 (at any time after ninety (90) days after the effective date of
the registration statement relating to the Company's IPO, and of the Securities
Act and the Exchange Act (at any time after it has become subject to such
reporting requirements), a copy of the most recent annual or quarterly report of
the Company, and such other reports and documents of the Company and other
information in the possession of or

                                       10
<PAGE>   11

reasonably obtainable by the Company as such party may reasonably request in
availing itself of any rule or regulation of the Commission allowing such party
to sell any such securities without registration.

                  1.10     Transfer of Registration Rights. Subject to Section 3
hereof, the rights to cause the Company to register securities granted to a
party under sections 1.2, 1.3 and 1.4 may be assigned to a transferee or
assignee reasonably acceptable to the Company in connection with any transfer or
assignment of Registrable Securities by such party provided that the transferor
provides the Company with written notice of the proposed transfer and: (i) the
transferee acquires all of the transferor's Registrable Securities; (ii) the
transferee acquires at least 200,000 shares (subject to adjustments for stock
splits, combinations, dividends or the like) of the transferor's Registrable
Securities; or (iii) the transferee is a partner, member, shareholder or
affiliate of the Holder who agrees to act through a single representative for
the purpose of such rights.

                  1.11     Standoff Agreement. Each Holder agrees, in connection
with the Company's IPO and upon request of the Company or the managing
underwriters in connection with one subsequent underwritten offering of the
Company's securities (provided that the underwriting agreement with respect to
such subsequent offering is executed not more than fifteen (15) months after the
closing of the Company's IPO), not to sell, make any short sale of, loan, grant
any option for the purchase of, or otherwise dispose of any Registrable
Securities (other than those included in the registration) without the prior
written consent of the Company or such underwriters, as the case may be, for up
to one hundred and eighty (180) days (ninety (90) days in the case of an
offering subsequent to the Company's IPO) following the effective date of the
registration statement of the Company filed under the Securities Act with
respect to such offering, and to enter into and be bound by such form of
agreement with respect to the foregoing as the underwriter may request;
provided, that the officers, directors and shareholders who hold 1% or more of
the outstanding capital stock of the Company also agree to such restrictions.

                  1.12     Termination. Any registration rights granted pursuant
to this Section 1 shall terminate (if not already terminated as provided herein)
and the Company shall have no obligations pursuant to Sections 1.2 through 1.4
with respect to: (i) any request or requests for registration made by any Holder
on a date more than three (3) years after the closing date of the Company's IPO
or (ii) any Registrable Securities proposed to be sold by a Holder in a
registration pursuant to Section 1.2, 1.3 or 1.4 if, in the opinion of counsel
to the Company, all Registrable Securities held by a Holder (and any affiliate
of the Holder with whom such Holder must aggregate its sales under Rule 144) may
be sold without registration under the Securities Act pursuant to Rule 144(k).

                  1.13     Other Registration Rights. The Company shall not,
without the prior written consent of Holders of a majority of the Registrable
Securities then outstanding grant any registration rights superior to or on a
parity with the rights granted pursuant to this Section 1.

                                       11
<PAGE>   12

         2.       Certain Investors' Right of First Refusal Upon Issuance of
Securities by the Company.

                  2.1      Right of First Refusal. The Company hereby grants to
TPG, Motorola and each of the Seligman Funds or any of their transferees
pursuant to Section 2.1(f) hereof (collectively, hereinafter, the "Rights
Holders") the right of first refusal to purchase all or part of its pro rata
share of New Securities (as defined in this Section 2.1) which the Company may
after the date hereof, from time to time, propose to sell and issue. For
purposes of this right of first refusal, a pro rata share for a Rights Holder is
the ratio that the number of shares of Stock then held by such Rights Holder
bears to the sum of the total number of shares of Stock then outstanding.

                           (a)      "Equity Securities" shall mean any
securities having voting rights in the election of the Board of Directors of the
Company not contingent upon default or any other event, or any securities
evidencing an ownership interest in the Company, or any securities convertible
into or exercisable for any shares of the foregoing, or any securities issuable
pursuant to any agreement or commitment to issue any of the foregoing.

                           (b)      Except as set forth below, "New Securities"
shall mean any Equity Securities, whether now authorized or not. Notwithstanding
the foregoing, "New Securities" does not include (i) securities offered to the
public generally pursuant to an effective registration statement under the
Securities Act; (ii) the Conversion Stock; (iii) stock issued in connection with
any stock split, stock dividend or recapitalization by the Company, (iv) shares
of Common Stock issued to officers, directors, employees or consultants of the
Company pursuant to stock grants, stock purchase and stock option plans or other
stock incentive programs, agreements or arrangements approved by the Board of
Directors, (v) shares of Common Stock or Preferred Stock of the Company issued
to or issuable to, upon conversion, exercise or exchange of warrants, lenders in
connection with loan or lease agreements approved by the Board of Directors,
(vi) securities issued pursuant to the acquisition of all or part of another
company by the Company by merger or other reorganization, or issued in
connection with the purchase or license of assets from any person, institution,
corporation or other entity (including finder's fees to officers, directors or
employees of the Company, if applicable), pursuant to a transaction approved by
the Board of Directors, and (vii) securities issued in connection with a joint
venture, corporate partnering or other strategic relationship approved by the
Board of Directors. Issuances of equity securities by subsidiaries of the
Company shall not be governed by the terms of this Agreement, but shall be
governed by the right of first refusal contained in the Subscription Agreement.

                           (c)      In the event the Company proposes to
undertake an issuance of New Securities, it shall give each Rights Holder
written notice of its intention, describing the type of New Securities, and the
price and terms upon which the Company proposes to issue the same. Each Rights
Holder shall have twenty (20) days from the date of receipt of any such notice
to agree to purchase up to its respective pro rata share of such New Securities
for the price and upon the applicable terms specified in the notice by giving
written notice to the Company and stating therein the quantity of New Securities
to be purchased.

                                       12
<PAGE>   13

                           (d)      In the event a Rights Holder fails to
exercise the right of first refusal within said twenty (20) day period, the
Company shall have ninety (90) days thereafter to sell or enter into an
agreement (pursuant to which the sale of New Securities covered thereby shall be
closed, if at all, within fifteen (15) days from the date of said agreement) to
sell the New Securities not elected to be purchased by Rights Holders at the
price and upon the terms no more favorable to the purchasers of such securities
than specified in the Company's notice. In the event the Company has not sold
the New Securities within said ninety (90) day period (or sold and issued New
Securities in accordance with the foregoing within fifteen (15) days from the
date of said agreement), the Company shall not thereafter issue or sell any New
Securities, without first offering such securities in the manner provided above.

                           (e)      The right of first refusal granted under
this Section 2.1 shall expire upon the closing of the earlier of (i) the first
underwritten offering of the Company's securities to the public pursuant to an
effective registration statement under the Securities Act and (ii) a statutory
share exchange, consolidation or merger of this Company with or into any other
corporation or corporations (other than a wholly-owned subsidiary), or the sale,
transfer or other disposition of all or substantially all of the assets of this
Company.

                           (f)      Subject to Section 4 hereof, the right of
first refusal hereunder may be assigned to any affiliate of the Rights Holder or
to a transferee or assignee (other than a competitor of the Company as
reasonably determined by the Company in good faith) in connection with any
transfer or assignment of Registrable Securities provided that (1) the
transferor provides the Company with written notice of the proposed transfer and
(2) the transferee acquires at least 1,000,000 shares (subject to adjustments
for stock splits, combinations, dividends or the like) of the transferor's
Registrable Securities.

         3.       Information Rights.

                  3.1      Annual Financial Information. The Company shall
deliver to each Rights Holder within ninety (90) days after the end of each
fiscal year, income, shareholders' equity and cash flow statements of the
Company for such year, and a balance sheet of the Company as of the end of such
year, such year-end financial reports to be in reasonable detail, prepared in
accordance with generally accepted accounting principles ("GAAP"), and certified
by independent public accountants of national standing selected by the Company's
Board of Directors.

                  3.2      Quarterly Financial Information. Within forty-five
(45) days after the quarterly accounting period of the Company, the Company
shall deliver to each Rights Holder an unaudited quarterly report including a
balance sheet, income statement and cash flow statement.

                  3.3      Annual Financial Plan. At least thirty (30) days
prior to the end of the fiscal year, the Company shall provide each Rights
Holder with the Company's annual financial plan for the next fiscal year as
approved by the Company's Board of Directors.

                                       13
<PAGE>   14

                  3.4      Inspection. The Company shall permit any Rights
Holder, at such Rights Holder's expense, to visit and inspect the Company's
properties, to examine its books of account and records and to discuss the
Company's affairs, finances and accounts with its officers, all at such
reasonable times as may be requested by the Investor; provided, however, that
the Company shall not be obligated pursuant to this Section 3.4 to provide
access to any information which it reasonably considers confidential
information.

                  3.5      Additional Information. If the Company files a
registration statement under the Securities Act for purposes of a public
offering of securities of the Company, the Company shall notify the Rights
Holders via facsimile within twenty-four (24) hours of such filing.

                  3.6      Termination of Information Covenants and
Confidentiality of Information. The covenants of the Company set forth in this
Section 3 shall terminate as to all Rights Holders and be of no further force or
effect (i) upon the consummation by the Company of the IPO (as defined in
subsection 1.2 above), (ii) upon the consummation of a merger or acquisition in
which the holders of a majority of the Company's voting securities prior to the
transaction do not hold a majority of the Company's voting securities following
the transaction, or (iii) when the Company first becomes subject to the periodic
reporting requirements of Section 12(g) or 15(d) of the Securities Exchange Act
of 1934, as amended (the "1934 Act"), whichever event shall first occur. Each
Rights Holder agrees that it will keep confidential and will not disclose or
divulge any confidential, proprietary or secret information which such Rights
Holder may obtain from the Company, and which the Company has prominently marked
"confidential", "proprietary" or "secret," pursuant to financial statements,
reports and other materials submitted by the Company as required hereunder
(collectively "Confidential Information"), unless such information is or becomes
known to the Rights Holder from a source other than the Company without
violation of any rights of the Company, or is or becomes publicly known, or
unless the Company gives its written consent to the Rights Holder's release of
such information, except that no such written consent shall be required (and the
Rights Holder shall be free to release such information to such recipient) if
such information is to be provided (i) to the Rights Holder's board of
directors, investment advisers, attorneys, accountants, consultants and other
professionals to the extent necessary to obtain their services in connection
with its investment in the Company, provided that such persons agree to hold
such information confidential as provided in this Section, (ii) to any
prospective purchaser of any shares of the Company owned by the Rights Holder
(other than a competitor of the Company as reasonably determined by the Company
in good faith) as long as such prospective purchaser agrees in writing to be
bound by the confidentiality provisions of this Section, (iii) to any of the
Rights Holder's affiliates, (other than a competitor of the Company as
reasonably determined by the Company in good faith) provided that such
affiliates agree to hold such information confidential as provided in this
Section, or (iv) as required by applicable law or regulation, regulatory body,
stock exchange, court or administrative order, or any listing or trading
agreement concerning the Rights Holder or the Company, provided that such Rights
Holder provides written notice to the Company prior to such disclosure. Any
Rights Holder receiving Confidential Information agrees to use such information
solely in connection with its investment in the Company.

                                       14
<PAGE>   15

         4.       Miscellaneous.

                  4.1      Assignment. The rights under this Agreement may be
assigned only in accordance with the transfer of rights provisions contained
elsewhere in this Agreement and to (i) a shareholder, partner, member, or
beneficiary of a Holder; (ii) a spouse, child, parent or beneficiary of the
estate of a Holder, (iii) an affiliate (as defined for purposes of Rule 144 of
the Securities Act) of the Holder; or (iv) a trust for the benefit of the
persons set forth in (i) or (ii); provided, however, that no party may be
assigned any of the foregoing rights unless the Company is given written notice
by the assigning party at the time of such assignment stating the name, address
and tax identification number of the assignee and identifying the securities of
the Company as to which the rights in question are being assigned; and provided
further that any such assignee shall receive such assigned rights subject to all
the terms and conditions of this Agreement, including without limitation the
provisions of this Section 4.

                  4.2      Governing Law. This Agreement shall be governed in
all respects by the laws of the State of Florida as applied to transactions
taking place between Florida residents and wholly within the State of Florida,
excluding that body of law relating to conflict of laws and choice of law.

                  4.3      Survival. The representations, warranties, covenants
and agreements made herein shall survive any investigation made by any Investor
and the closing of the transactions contemplated hereby.

                  4.4      Successors and Assigns. Except as otherwise provided
herein, the provisions hereof shall inure to the benefit of, and be binding
upon, the successors, assigns, heirs, executors and administrators of the
parties hereto.

                  4.5      Determination of Share Amounts. To determine the
number of Registrable Securities held by a Holder for purposes of this
Agreement, all Registrable Securities held by an affiliate of the Holder shall
be deemed held by such Holder. For purposes of this Section 5.4, "affiliate"
shall mean a person that directly, or indirectly through one or more
intermediaries, controls, or is controlled by, or is under common control with,
such Holder and shall include all partners and members of such Holder. Further,
in making such determination, all Registrable Securities held by the Seligman
Funds shall be deemed held by a single Holder.

                  4.6      Entire Agreement; Amendment. This Agreement
constitutes the full and entire understanding and agreement between the parties
with regard to the subjects hereof, and no party shall be liable or bound to any
other party in any manner by any warranties, representations or covenants except
as specifically set forth herein. With the written consent of the record or
beneficial holders of at least fifty percent (50%) of the Registrable Securities
held by the Investors, the obligations of the Company and the rights of the
Holders under this Agreement may be waived (either generally or in a particular
instance, either retroactively or prospectively, and either for a specified
period of time or indefinitely), and with the same consent the Company, when
authorized by resolution of its Board of Directors, may enter into a
supplementary agreement for the purpose of adding any provisions to or changing
in any manner or eliminating

                                       15
<PAGE>   16

any of the provisions of this Agreement. Notwithstanding anything else in this
Section 4.6, no Investor shall have the benefit of the rights provided for in
this Agreement until such Investor has executed and delivered to the Company a
signature page to this Agreement. Notwithstanding anything else in this Section
4.6, this Agreement may not be amended so as to adversely affect the rights of
any Rights Holder without the consent of such Rights Holder.

                  4.7      Notices, etc. All notices and other communications
required or permitted hereunder shall be in writing and shall be delivered
personally, via facsimile with confirmation of transmission, mailed by first
class mail, postage prepaid, or delivered by courier or overnight delivery,
addressed (a) if to an Investor, at such party's address as set forth on the
signature page of such party hereto, or, if no address is provided on such page,
in the Company's records, or at such other address or facsimile number as such
party shall have furnished to the Company in writing or (b) if to the Company,
at GMP Companies, Inc., One East Broward Blvd., Ft. Lauderdale, Florida 33301,
or such address as the Company shall have furnished to the Investor in writing.
Notices that are mailed shall be deemed received five (5) days after deposit in
the United States mail.

                  4.8      Delays or Omissions. Except as expressly provided
herein, no delay or omission to exercise any right, power or remedy accruing to
any holder of any shares, upon any breach or default of the Company under this
Agreement, shall impair any such right, power or remedy of such holder nor shall
it be construed to be a waiver of any such breach or default, or an acquiescence
therein, or of or in any similar breach or default thereafter occurring; nor
shall any waiver of any single breach or default be deemed a waiver of any other
breach or default theretofore or thereafter occurring. Any waiver, permit,
consent or approval of any kind or character on the part of any holder of any
breach or default under this Agreement, or any waiver on the part of any holder
of any provisions or conditions of this agreement, must be in writing and shall
be effective only to the extent specifically set forth in such writing. All
remedies, either under this Agreement or by law or otherwise afforded to any
holder, shall be cumulative and not alternative.

                  4.9      Counterparts. This Agreement may be executed in any
number of counterparts, each of which shall be an original, but all of which
together shall constitute one instrument.

                  4.10     Severability. If any provision of this Agreement, or
the application thereof, shall for any reason and to any extent be invalid or
unenforceable the remainder of this Agreement and application of such provision
to persons or circumstances shall be interpreted so as best to reasonably effect
the intent of the parties hereto, the parties further agree to replace such void
or unenforceable provision of this Agreement with a valid and enforceable
provision which will achieve to the extent possible, the economic, business and
other purposes of the void or unenforceable provision.

                  4.11     Titles and Subtitles. The titles and subtitles used
in this Agreement are used for convenience only and are not considered in
construing or interpreting this Agreement.

                                       16
<PAGE>   17

                  4.12     Attorney's Fees. If any action at law or in equity
(including arbitration) is necessary to enforce or interpret the terms of this
Agreement, the prevailing party shall be entitled to reasonable attorney's fees,
costs and necessary disbursements in addition to any other relief to which such
party may be entitled.

         IN WITNESS WHEREOF, the parties hereto have executed this Investors'
Rights Agreement as of the date set forth in the first paragraph hereof.

                                          COMPANY:

                                          GMP COMPANIES, INC.

                                          By:
                                             ----------------------------------
                                             Bart Chernow, M.D.
                                             President and Chief Executive
                                             Officer

                                       17
<PAGE>   18

                          COUNTERPART SIGNATURE PAGE TO
                           INVESTORS' RIGHTS AGREEMENT

                                     INVESTOR:

                                             MOTOROLA, INC.

                                             ----------------------------------
                                             By:

                                             Title:

                                             Address:

                                             Motorola, Inc.
                                             Motorola Millenium Ventures
                                             1303 E. Algonquin Road
                                             Schaumburg, Illinois  60196
                                             Attention: Rud Istvan
                                             Fax: (847) 538-2250

                                             with a copy to:

                                             Motorola, Inc.
                                             Corporate Law Department
                                             1303 E. Algonquin Road
                                             Schaumburg, Illinois  60196
                                             Attention:  General Counsel
                                             Fax: (847) 576-3628

                                       18
<PAGE>   19

                          COUNTERPART SIGNATURE PAGE TO
                           INVESTORS' RIGHTS AGREEMENT

                                  INVESTOR:

                                         SELIGMAN COMMUNICATIONS AND
                                         INFORMATION FUND, INC.

                                         --------------------------------------
                                         By: J.& W. SELIGMAN & CO.
                                         INCORPORATED, its Investment Advisor

                                         By:
                                            -----------------------------------

                                         Title:
                                               --------------------------------

                                         Address:
                                         100 Park Avenue
                                         New York, N.Y. 10017
                                         fax: (212) 922-5731
                                         attn:  Jim Curtis

                                       19
<PAGE>   20

                          COUNTERPART SIGNATURE PAGE TO
                           INVESTORS' RIGHTS AGREEMENT

                                  INVESTOR:

                                         SELIGMAN  NEW TECHNOLOGIES FUND,
                                         INC.

                                         --------------------------------------
                                         By: J.& W. SELIGMAN & CO.
                                         INCORPORATED, its Investment Advisor

                                         By:
                                            -----------------------------------

                                         Title:
                                               --------------------------------

                                         Address:
                                         100 Park Avenue
                                         New York, N.Y. 10017
                                         fax: (212) 922-5731
                                         attn:  Jim Curtis

                                       20
<PAGE>   21

                          COUNTERPART SIGNATURE PAGE TO
                           INVESTORS' RIGHTS AGREEMENT

                                  INVESTOR:

                                         SELIGMAN INVESTMENT
                                         OPPORTUNITIES (MASTER) FUND - NTV
                                         PORTFOLIO

                                         --------------------------------------
                                         By: J.& W. SELIGMAN & CO.
                                         INCORPORATED, its Investment Advisor

                                         By:
                                            -----------------------------------

                                         Title:
                                               --------------------------------

                                         Address:
                                         100 Park Avenue
                                         New York, N.Y. 10017
                                         fax: (212) 922-5731
                                         attn:  Jim Curtis

                                       21
<PAGE>   22

                          COUNTERPART SIGNATURE PAGE TO
                           INVESTORS' RIGHTS AGREEMENT

                                  INVESTOR:

                                    TPG PARTNERS III, L.P.

                                    By:  TPG GenPar III, L.P.
                                         General Partner

                                         By: TPG Advisors III, Inc.
                                             General Partner

                                    By:
                                       ----------------------------------------
                                    Name:
                                    Title:

                                    Address:
                                    201 Main Street
                                    Suite 2420
                                    Fort Worth, Texas 76102

                                       22
<PAGE>   23

                          COUNTERPART SIGNATURE PAGE TO
                           INVESTORS' RIGHTS AGREEMENT

                                     INVESTOR:

                                             FUQUA VENTURE PARTNERS, LLC

                                             ----------------------------------
                                             By:

                                             Title:  Managing Director

                                             Address:
                                             1201 W. Peachtree Street
                                             Suite 5000
                                             Atlanta, GA  30309
                                             Fax:  404-815-4528

                                       23<PAGE>   1
                                                                   EXHIBIT 10.20

                               STRATEGIC AGREEMENT

         This Strategic Agreement (this "AGREEMENT") is made and entered into as
of the 15th day of July, 2000 (the "EFFECTIVE DATE"), by and between Myriad
Genetic Laboratories, Inc., a Delaware corporation with its principal place of
business at 320 Wakara Way, Salt Lake City, Utah 84108 ("MYRIAD") and
GMP|Genetics, Inc., a Delaware corporation with its principal place of business
at One East Broward Boulevard, Suite 1701, Ft. Lauderdale, Florida 33301
("GMP|GENETICS"), a subsidiary of GMP Companies, Inc., a Delaware corporation
with its principal place of business at One East Broward Boulevard, Suite 1701,
Ft. Lauderdale, Florida 33301 ("GMP COMPANIES"). Myriad and GMP|Genetics are
each individually referred to herein as a "PARTY" and collectively as the
"PARTIES."

                                    RECITALS

         WHEREAS, Myriad is engaged in the business of providing accurate and
timely results for molecular diagnostic tests, including tests for breast and
ovarian cancer ("BRCA1 and BRCA2") and hereditary non-polyposis colon cancer
("MLH1 and MSH2");

         WHEREAS, GMP Companies and GMP|Genetics is engaged in the business of
developing and commercializing technologies for performing genetics tests and
possesses gene separation ("Conversion") technology ("GMP Conversion
Technology(TM)") for genetic analysis; and

         WHEREAS, the Parties desire to enter into a strategic relationship to
evaluate GMP Conversion Technology(TM) in order to enhance the subsequent
molecular diagnostic testing performed by Myriad.

         NOW, THEREFORE, in consideration of the foregoing and the covenants and
premises contained in this Agreement, the Parties agree as follows:

                                    AGREEMENT

1.       DEFINITIONS

         1.1 "EVALUATION PERIOD" shall mean the period commencing on the date
hereof and ending 120 days following such date or upon completion of the
Evaluation.

         1.2 "GMP|GENETICS CONFIDENTIAL INFORMATION" shall mean all GMP|Genetics
proprietary information, technical data, trade secrets or know-how, including,
but not limited to, research, product plans, products, services, customer lists
and customers, markets, software, developments, inventions, processes, formulae,
technology, designs, drawings engineering, hardware configuration information,
marketing, finances or other business information disclosed to Myriad either
directly or indirectly in writing, or by drawings or observations of parts,
equipment or processes, or, if disclosed orally, confirmed in writing within 30
days of disclosure.

         1.3 "MYRIAD CONFIDENTIAL INFORMATION" shall mean all Myriad proprietary
information, technical data, trade secrets or know-how, including, but not
limited to, research, product plans, products, services, customer lists and
customers, markets, software, developments, inventions, processes, formulae,
technology, designs, drawings, engineering, hardware configuration information,
marketing, finances or other business information disclosed to GMP|Genetics
either directly or indirectly in writing, or by drawings or observations of
parts, equipment or processes, or, if disclosed orally, confirmed in writing
within 30 days of disclosure.

<PAGE>   2

2.       VALIDATION AND RESEARCH COLLABORATION

         2.1 GENERAL. It is the intention of the Parties to conduct a series of
studies and experiments for the purposes of: (i) ensuring that materials
submitted to GMP|Genetics for Conversion are properly handled in compliance with
all applicable law and governmental regulations and guidelines; (ii) determining
the effectiveness of the use of GMP Conversion Technology(TM) in combination
with the genetic tests performed by Myriad; (iii) determining the commercial
feasibility of a combination Myriad/GMP|Genetics testing service, including cost
and turnaround time(the "Evaluation").

         2.2 RESEARCH SAMPLES. GMP|Genetics shall notify Myriad in writing of
the date (the "INITIAL ACCEPTANCE DATE") on which the laboratory at which the
Conversion shall be performed (the "GMP|GENETICS Laboratory") will be ready to
accept samples. The notice referred to in the immediately preceding sentence
shall be given not later than fifteen (15) days prior to the Initial Acceptance
Date. GMP|Genetics shall initially send to Myriad, thirty (30) specimens for
full sequence analysis ("INITIAL EVALUATION"). Each specimen shall consist of a
triplet: an unconverted specimen, a converted (paternal) and a converted
(maternal) specimen. Myriad will perform subsequent sequencing on each of these
triplet specimens. Myriad will provide GMP with copies of all test results and
reports.

         2.3 QUALITY ASSURANCE AND AUTOMATION VALIDATION. During the Evaluation
Period, and upon mutual agreement of the Parties, each Party will have the right
to visit the facilities of the other Party to review the laboratory's facilities
and procedures in place for ensuring that specimens are being handled in
compliance with all applicable law and governmental regulations and guidelines
and applicable quality control standards. In addition, the Parties shall meet
from time to time to review Evaluation results and operating procedures and
discuss matters of common concern related to the tests and processes to be
employed by the respective Parties. The Parties acknowledge that it is of utmost
importance to ensure that the highest standards are adhered to in the handling
of the samples and the performance of the Conversion and subsequent genetic
testing.

         2.4 CONTEMPLATED SPECIMENS. It is contemplated that the types of
specimens that will be sent by Myriad to GMP|Genetics for Conversion processing
during the Evaluation Period will include anonymous research specimens from high
risk families that do not yet have any apparent mutations in the coding region
of the genes.

         2.5 PRICING AND PAYMENT TERMS DURING EVALUATION PERIOD. Following
successful completion of the Initial Evaluation and upon mutual agreement,
Myriad and GMP|Genetics will evaluate the commercial feasibility on an
additional seventy (70) individual DNA samples, which will be converted by
GMP|Genetics and sequenced by Myriad. Myriad will pay Three Hundred Dollars
($300.00) to GMP|Genetics for the conversion of each of these samples.
GMP|Genetics will submit a monthly invoice to Myriad showing the number of
Conversions performed and the amount due to GMP|Genetics. The invoiced amount
will be due and payable within thirty (30) days of the date of the invoice. Late
charges on past due invoices may be assessed at a rate of one and one-half
percent per month. GMP|Genetics shall have the right to cease performance of
services hereunder in the event Myriad has not paid an overdue invoice;
provided, however, that GMP|Genetics shall not be entitled to cease performance
if Myriad's failure to pay an overdue invoice is due to a good faith dispute
between the parties concerning the content or calculation of any invoice.

During the term of this agreement, Myriad agrees to accept approximately 100
additional DNA samples from a Johns Hopkins research study for MLH1 and MSH2
testing analysis which have been previously

                                       2

<PAGE>   3

submitted to GMP|Genetics for Conversion. Myriad agrees to charge the researcher
$650 for each such analysis.

         2.6 INTELLECTUAL PROPERTY MATTERS. Any Intellectual Property resulting
from defined research study and which is invented jointly by both Parties will
be jointly owned by the Parties.

         2.7 CONFIDENTIALITY.

             2.7.1 MYRIAD OBLIGATIONS. Myriad shall maintain in strict
confidence all GMP|Genetics Confidential Information and the Evaluation data and
results to the same extent and in the same manner Myriad maintains its own
confidential information and shall not use GMP|Genetics Confidential Information
received from GMP|Genetics during the term of this Agreement, except as
otherwise provided for in this Agreement.

             2.7.2 GMP|GENETICS OBLIGATIONS. GMP|Genetics shall maintain in
strict confidence all Myriad Confidential Information and the Evaluation data
and results to the same extent and in the same manner GMP|Genetics maintains its
own confidential information and shall not use Myriad Confidential Information
received from Myriad during the term of this Agreement, except as otherwise
provided for in this Agreement.

             2.7.3 EXCEPTIONS. Non-disclosure and non-use obligations of Myriad
and GMP|Genetics shall not apply to Myriad Confidential Information or
GMP|Genetics Confidential Information that:

             (a) was known to the receiving Party, as shown by prior written
         records, or to the public prior to the disclosure by the disclosing
         Party; or

             (b) becomes known to the public from a source other than the
         receiving Party; or

             (c) is disclosed to the receiving Party by a third party having a
         legal right to make the disclosure;

             (d) is required by law to be disclosed.

             2.7.4 PUBLICATIONS. Except as otherwise provided in this Agreement,
the Parties shall collaborate on any press releases or other publication or
dissemination of information that relates to this Agreement or the relationship
of the Parties, including work performed on behalf of Johns Hopkins under
Paragraph 2.5. No such press releases or other publication or dissemination of
information, including Evaluation data and results, shall be made without the
consent of both Parties, unless advised by counsel that the same is required by
applicable law or compelled by court order.

3.       LICENSE TO GMP CONVERSION TECHNOLOGY(TM); COMMERCIAL SERVICES

         3.1 OPTION GRANT. GMP|Genetics hereby grants to Myriad an option
exercisable during the term of this Agreement to obtain commercial Conversion
services from GMP|Genetics, and to obtain a world-wide license under
GMP|Genetics' GMP Conversion Technology(TM) for research and commercial use by
Myriad upon the terms specified below.

         3.2 CONVERSION SERVICES. Subject to the provisions of this Section 3
and following demonstration of acceptable quality on the part of GMP|Genetics
and at Myriad's sole discretion, Myriad shall have the right to obtain from
GMP|Genetics commercial Conversion services with respect

                                       3

<PAGE>   4

to specimens that are to be tested by Myriad for BRCA1 and BRCA2, MLH1 and MSH2,
or other genetic tests performed by Myriad. GMP|Genetics will perform the
Conversion on the samples and will return the converted samples to Myriad for
subsequent sequencing pursuant to the pricing and payments terms specified
below.

         3.3      PRICING AND PAYMENT TERMS.

                  3.3.1    COMMERCIAL PRICING. Following the Evaluation, Myriad
                           and GMP/Genetics shall negotiate preferred pricing
                           for a mutually beneficial commercial relationship.

                  3.3.2    QUARTERLY ACCOUNTING. Within sixty (60) days of the
                           end of each three-month period following the end of
                           the Evaluation Period, Myriad will submit to
                           GMP|Genetics an accounting of all amounts charged by
                           Myriad to its customers for performing genetic tests
                           on samples which were submitted to GMP|Genetics for
                           conversion, as well as a statement of amounts which
                           would be due to GMP|Genetics under clause 3.3.1(ii)
                           above, including such schedules and data as may be
                           appropriate to support such calculation (the
                           "QUARTERLY STATEMENT"). If the amounts due as
                           aforesaid are greater than the amounts invoiced by
                           GMP|Genetics under Section 3.3.1 above, Myriad shall
                           promptly pay the excess amount to GMP|Genetics. The
                           excess, if any, of the amounts due to GMP|Genetics as
                           calculated in accordance with the immediately
                           preceding sentence over the amounts invoiced pursuant
                           to Paragraph 3.3.1 above shall be referred to herein
                           as the "INVOICE ADJUSTMENT." GMP|Genetics and its
                           accountants shall be entitled to review the Quarterly
                           Statement and any working papers, trial balances and
                           similar materials relating to the calculation of the
                           Invoice Adjustment prepared by Myriad or its
                           accountants. Myriad shall also provide GMP|Genetics'
                           accountants, as approved by Myriad, with timely
                           access, during Myriad's normal business hours, to
                           Myriad's personnel, properties, books and records to
                           the extent related to the preparation of the Invoice
                           Adjustment once each year. GMP|Genetics shall not
                           have any right to audit the books of Myriad earlier
                           than three (3) years prior to the date on which such
                           audit is conducted.

                  3.3.3    DISPUTES. Disputes between the Parties with respect
                           to the determination of the Invoice Adjustment shall
                           be resolved by arbitration in the manner set forth in
                           Section 9.2 below. The costs and expenses related to
                           the arbitration proceeding (including reasonable
                           attorneys' fees and costs) will be borne (a) by
                           Myriad, if the final Invoice Adjustment as determined
                           in the arbitration proceeding exceeds the Invoice
                           Adjustment calculated by Myriad pursuant to Section
                           3.3.2 above by ten percent (10%) or more, or (b) by
                           GMP|Genetics, if the final Invoice Adjustment as
                           determined in the arbitration proceeding is less than
                           the Invoice Adjustment calculated by myriad pursuant
                           to Section 3.3.2 above by ten percent (10%) or more,
                           or (c) equally by Myriad and GMP|Genetics if neither
                           (a) nor (b) of this Section 3.3.3 is applicable.

         3.4      LICENSE TERMS. In the event that Myriad elects to exercise its
option to obtain a world-wide non-exclusive license from GMP|Genetics to utilize
GMP Conversion Technology(TM) for its own research and commercial use, Myriad
and GMP|Genetics shall negotiate in good faith the terms of such license.

                                       4

<PAGE>   5

4.       COLLABORATIVE MARKETING ACTIVITIES

         4.1 MARKETING TO NIH. Myriad has entered into a Memorandum of
Understanding with the National Institute of Health (the "NIH") pursuant to
which Myriad performs BRCA1 and BRCA2 sequencing analyses for a preferred price
to scientists that are funded by the NIH. Myriad and GMP|Genetics will jointly
contact the NIH to offer Conversion services with respect to genetic testing
conducted by Myriad.

         4.2 MARKETING TO OTHER THIRD PARTIES. The Parties shall further
collaborate to make the Conversion services available to the research community
for research purposes only.

         4.3 PRICING. In the event that the Parties successfully negotiate to
sell Conversion services to any third party, Myriad will charge such Third Party
for Conversion services, and will be responsible for all payments to
GMP|Genetics for such Conversion services, as specified in Section 3.3.1 above.

5.       NO REPRESENTATION OR WARRANTY. GMP|Genetics makes no representation or
warranty with respect to the performance of cell lines it produces which are
haploid for one or more human chromosomes, including their safety, effectiveness
or commercial viability. GMP|GENETICS DISCLAIMS ALL WARRANTIES WITH REGARD TO
PRODUCTS, SERVICES AND PROCESSES PROVIDED BY IT UNDER THIS AGREEMENT, INCLUDING,
BUT NOT LIMITED TO, ALL WARRANTIES, EXPRESS OR IMPLIED, OF MERCHANTABILITY AND
FITNESS FOR ANY PARTICULAR PURPOSE, NOTWITHSTANDING ANY OTHER PROVISION OF THIS
AGREEMENT. GMP|Genetics additionally disclaims all obligations and liabilities
for losses or damages, including, but not limited to, direct, indirect, special
and consequential damages, attorneys' and experts' fees, and court costs arising
out of or in connection with the products, services and processes provided by it
under this Agreement. Myriad assumes all responsibility and liability, including
claims and actions by third parties, for loss or damage claimed or caused by a
cell line and/or process that, directly or indirectly, is manufactured, used or
sold by Myriad in connection with this Agreement.

6.       INDEMNIFICATION. a) Myriad shall defend, indemnify and hold
GMP|Genetics and its successors and assigns and its and their respective
officers, directors, shareholders, employees and agents harmless from and
against all liability, demands, damages, expenses and losses for death, personal
injury, mental or physical illness or property damage or claims as to the same
arising out of or in connection with Myriad's products, services or processes
arising directly or indirectly from this Agreement, except for matters for which
GMP|Genetics has indemnified Myriad under paragraph b) below.

                          b) GMP|Genetics shall defend, indemnify and hold
Myriad and its successors and assigns and its and their respective officers,
directors, shareholders, employees and agents harmless from and against all
liability, demands, damages, expenses and losses for death, personal injury,
mental or physical illness or property damage or claims as to the same
proximately caused by the GMP Conversion Technology(TM) services performed under
this Agreement.

7.       TERM. This Agreement shall terminate one year from the Effective Date
of this Agreement. This Agreement may be extended thereafter upon mutual written
agreement of the Parties, subject to the right of either Party to terminate this
Agreement upon ninety (90) days' written notice to the other Party.
Notwithstanding the foregoing, either Party may terminate this Agreement
immediately

                                       5

<PAGE>   6

upon notice in the event of a breach by the other Party of this Agreement in any
material respect if the same has not been cured within thirty (30) days after
written notice of the breach is given.

8.       MISCELLANEOUS.

         8.1 PROMOTION OF RELATIONSHIP. During the Evaluation Period Myriad and
GMP|Genetics will each separately and jointly promote and publicize the
strategic relationship and purposes of this Strategic Agreement to third
parties, under terms mutually agreeable to the Parties.

         8.2 NO AGENCY. It is understood and agreed that nothing in this
Agreement shall be construed as authorization for either Myriad or GMP|Genetics
to act as agent for the other Party to this Agreement. Myriad shall not incur
any liability for any act or failure to act by employees of GMP|Genetics.
GMP|Genetics shall not incur any liability for any act or failure to act by
employees of Myriad.

         8.3 DISPUTE RESOLUTION. Other than with respect to matters arising
under Paragraphs 3.3 and 3.4 above, any dispute, controversy or claim arising
out of or relating to this Agreement shall be settled first by recourse to the
Chief Executive Officers of each Party, who shall attempt in good faith to
resolve any disputes between the Parties, and then, if such attempts to resolve
any such dispute are unsuccessful, by arbitration under the rules of the
American Arbitration Association. All awards of the arbitrators shall be final
and binding on the parties and enforceable in any court of competent
jurisdiction. Nothing herein shall prevent a Party from seeking injunctive
relief, where appropriate, from a court of competent jurisdiction pending the
outcome of any arbitration concerning the subject of such arbitration or when
authorized by an arbitrator's award or when emergency relief is required.

         8.4 BRANDING. Myriad shall credit GMP|Genetics as the source of the GMP
Conversion Technology(TM) in all of Myriad's promotional material and any other
materials intended for distribution to any person or entity other than one of
the Parties. GMP|Genetics shall credit Myriad as the source of the full sequence
tests in all of GMP|Genetics' promotional material and any other materials
intended for distribution to any person or entity other than one of the Parties.

         8.5 CHAIN OF CUSTODY. The Parties will work together to jointly develop
procedures intended to ensure that samples are handled in compliance with all
applicable law and governmental regulations and guidelines, and ensure the
integrity of the results of the Conversion.

         8.6 FORCE MAJEURE. All Parties to the Agreement shall be excused from
the performance of their obligations under this Agreement if such performance is
prevented by Force Majeure and the non-performing Party promptly provides notice
of the prevention to the other Party. Such excuse shall be continued so long as
the condition constituting Force Majeure continues and the non-performing Party
takes reasonable efforts to remove the condition. For purposes of this
Agreement, Force Majeure shall include conditions beyond the control of the
Parties, including without limitation, an act of God, voluntary or involuntary
compliance with any regulation, law, or order of any government, war, civil
commotion, epidemic, failure or default of public utilities or common carriers,
destruction of production facilities or materials by fire, earthquake, storm, or
like catastrophe.

         8.7 AMENDMENT. This Agreement may not be amended, supplemented, or
otherwise modified except by an instrument in writing signed by all Parties.

                                       6

<PAGE>   7

         8.8 NOTICES. Any notice required or permitted to be given under this
Agreement shall be in writing and shall be deemed to have been sufficiently
given for all purposes if mailed by first class, certified or registered mail,
postage prepaid, or if transmitted via facsimile with confirmation of successful
transmission. Unless otherwise specified in writing, the mailing addresses of
the parties shall be as described below:

FOR MYRIAD:                Myriad Genetic Laboratories, Inc.
                           320 Wakara Way
                           Salt Lake City, UT 84108
                           Attn:  President

FOR GMP|GENETICS:
                           GMP|Companies, Inc.
                           One East Broward Blvd., Suite 1701
                           Fort Lauderdale, FL 33301
                           Attn:  Michael Salem, M.D.
                                  Executive Vice President

         8.9 ASSIGNMENT. Neither Party may not assign its rights and obligations
under this Agreement without the prior written consent of the others Party,
except in connection with any merger, reorganization, or sale of all or
substantially all of its assets. This Agreement shall be binding upon and shall
inure to the benefit of the successors and permitted assigns of the Parties.

         8.11 CONSENTS NOT UNREASONABLY WITHHELD.Whenever provision is made in
this Agreement for any Party to secure the consent or approval of another, that
consent or approval shall not unreasonably be withheld, and whenever in this
Agreement provisions are made for one Party to object to or disapprove a matter,
such objection or disapproval shall not unreasonably be exercised.

         8.12 NO STRICT CONSTRUCTION. This Agreement has been prepared jointly
and shall not be strictly construed against any Party.

         8.13 HEADINGS. The captions or headings of the Sections or other
subdivisions hereof are inserted only as a matter of convenience or for
reference and shall have no effect on the meaning of the provisions hereof.

         8.14 SEVERANCE OF CLAUSES. All Parties agree that, should any provision
of this Agreement be determined by a court of competent jurisdiction to violate
or contravene any applicable law or policy, such provision will be severed or
modified by the court to the extent necessary to comply with the applicable law
or policy, and such modified provision and the remainder of the provisions
hereof will continue in full force and effect.

         8.15 WAIVER. The waiver of a breach hereunder may be effected only by a
writing signed by the waiving Party and shall not constitute a waiver of any
other breach.

         8.16 ENTIRE AGREEMENT. This Agreement and the attachments hereto and
other agreements executed by the Parties or affiliates entities this even date
constitute the entire agreement of the Parties relating to the subject matter
and supercede any prior agreements relating to the subject matter hereof.

                                       7

<PAGE>   8

         8.17 COUNTERPARTS. This Agreement may be executed in one or more
counterparts, each of which shall constitute an original, but which together
shall constitute the same instrument.

         8.18 SURVIVING RIGHTS. Termination, expiration, or cancellation of this
Agreement by any Party shall not relieve the Parties of any rights or
obligations accrued hereunder prior to such termination, expiration, or
cancellation.

         8.19 INSURANCE. Each Party shall maintain general commercial and
product liability insurance in amounts sufficient to cover reasonably
anticipated claims and liability arising under or related to the subject of this
Agreement.

         IN WITNESS WHEREOF, the Parties by their respective authorized
officers, have executed this Agreement.

MYRIAD GENETIC LABORATORIES, INC.           GMP|GENETICS, INC.

By:                                         By:
   ---------------------------------------     --------------------------------
     Gregory C. Critchfield, M.D., M.S.,         Bart Chernow, M.D., President
     President

                                       8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00016-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00016-of-00352.parquet"}]]